I agree with you completely. I would add, that
Post# of 148182
(Total Views: 699)
Posted On: 11/17/2020 4:43:56 PM
Re: Boatbuilder #65791
I agree with you completely.
I would add, that if were to jump forward in time a year, we may very well have a handle" on COVID, but we may also have accepted the potential reality that COVID will be an endemic (every year), and as such we will need top tier therapeutics indefinitely.
I've said this before, but it bears repeating. If Leronlimab (Vyrologix) becomes the standard treatment for S/C, the endemic nature of this pandemic will introduce a multiple to the revenue equation.
It will also possibly open the door to use in other post viral inflammatory diseases as was alluded to in the video today. Again, another multiple.
Lastly, and most importantly (from a pure investment standpoint), the revenue from COVID, should we achieve it, will be a tremendous accelerant to the development of our drug for all of the other indications.
I would add, that if were to jump forward in time a year, we may very well have a handle" on COVID, but we may also have accepted the potential reality that COVID will be an endemic (every year), and as such we will need top tier therapeutics indefinitely.
I've said this before, but it bears repeating. If Leronlimab (Vyrologix) becomes the standard treatment for S/C, the endemic nature of this pandemic will introduce a multiple to the revenue equation.
It will also possibly open the door to use in other post viral inflammatory diseases as was alluded to in the video today. Again, another multiple.
Lastly, and most importantly (from a pure investment standpoint), the revenue from COVID, should we achieve it, will be a tremendous accelerant to the development of our drug for all of the other indications.
(5)
(1)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼